Scholar Rock Holding Corporation (SRRK)

NMS – Real vaqt narxi. Valyuta: USD

53.82

+1.75 (3.36%)

Yopilishda: Aug 12, 2026, 4:00 PM EDT

53.90

+0.08 (0.15%)

Bozordan keyin: Aug 12, 2026, 4:37 PM EDT

07.08.2026

Scholar Rock drops Catalent facility from marketing application for muscle weakness drug

Scholar Rock said on Friday it would remove Catalent's Indiana manufacturing facility from its application seeking FDA approval for a rare neuromuscular disease drug.

07.08.2026

Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its world-leading platform in myostatin biology, today announced that the FDA review of the apitegromab Biologics License Application (BLA) for the treatment of children and adults with spinal muscular atrophy (SMA) is progressing with the Company's second fill-finish facility. The B.

07.08.2026

Scholar Rock Q2 Earnings Call Highlights

Scholar Rock NASDAQ: SRRK said its resubmitted biologics license application for apitegromab remains on track for a U.S. Food and Drug Administration decision by its Sept. 30 PDUFA date, as the company prepares for a potential launch of the muscle-targeted treatment for spinal muscular atrophy, or SMA.

06.08.2026

Scholar Rock Holding Corporation (SRRK) Q2 2026 Earnings Call Transcript

06.08.2026

Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology, today reported financial results for the second quarter ended June 30, 2026, and provided an update on recent company developments. “We are on the threshold of securing the world's first ever regulatory approval of a myostatin inhibitor, whi.

Videolar

No Data

There is no data to display

Press-relizlar

07.08.2026

Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date

06.08.2026

Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology, today reported financial results for the second quarter ended June 30, 2026, and provided an update on recent company developments. “We are on the threshold of securing the world's first ever regulatory approval of a myostatin inhibitor, whi.

Scholar Rock Holding Corporation (SRRK)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Scholar Rock Holding Corporation (SRRK)

Scholar Rock drops Catalent facility from marketing application for muscle weakness drug

Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date

Scholar Rock Q2 Earnings Call Highlights

Scholar Rock Holding Corporation (SRRK) Q2 2026 Earnings Call Transcript

Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Videolar

No Data

Press-relizlar

Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date

Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Scholar Rock drops Catalent facility from marketing application for muscle weakness drug

Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date

Scholar Rock Q2 Earnings Call Highlights

Scholar Rock Holding Corporation (SRRK) Q2 2026 Earnings Call Transcript

Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Videolar

No Data

Press-relizlar

Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date

Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Search stocks

Scholar Rock Holding Corporation (SRRK)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Scholar Rock Holding Corporation (SRRK)

Scholar Rock drops Catalent facility from marketing application for muscle weakness drug

Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date

Scholar Rock Q2 Earnings Call Highlights

Scholar Rock Holding Corporation (SRRK) Q2 2026 Earnings Call Transcript

Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Videolar

No Data

Press-relizlar

Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date

Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Scholar Rock drops Catalent facility from marketing application for muscle weakness drug

Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date

Scholar Rock Q2 Earnings Call Highlights

Scholar Rock Holding Corporation (SRRK) Q2 2026 Earnings Call Transcript

Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Videolar

No Data

Press-relizlar

Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date

Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights